论文部分内容阅读
In the past ten years,the focus of anticancer drug development has shifted from chemotherapeutics to targeted therapeutics,including both small-molecules and biologics.However,the occasional success of the targeting strategy cannot hide the disappointing failures of many clinical candidates.The transition between preclinical development and successful clinical trials remains a big challenge in anti-cancer drug development.Many oncology research programs have relied heavily on cancer cell lines xenograft models to evaluate a candidate s therapeutic potential.